Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Non-Current Deffered Revenue for 13 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 3.68% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 3.68% increase, with the full-year FY2025 number at $2.7 million, up 3.68% from a year prior.
  • Non-Current Deffered Revenue was $2.7 million for Q4 2025 at Niagen Bioscience, roughly flat from $2.7 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.4 million in Q2 2021 to a low of $2.6 million in Q3 2024.
  • A 5-year average of $3.5 million and a median of $3.8 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: increased 16.26% in 2021, then plummeted 32.24% in 2024.
  • Niagen Bioscience's Non-Current Deffered Revenue stood at $4.3 million in 2021, then fell by 7.96% to $4.0 million in 2022, then dropped by 17.5% to $3.3 million in 2023, then dropped by 21.85% to $2.6 million in 2024, then increased by 3.68% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Non-Current Deffered Revenue are $2.7 million (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025).